Skip to content

Advertisement

  • Research
  • Open Access

Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study

  • 1,
  • 1,
  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Contributed equally
World Journal of Surgical Oncology201715:196

https://doi.org/10.1186/s12957-017-1264-7

  • Received: 20 March 2017
  • Accepted: 23 October 2017
  • Published:

Abstract

Background

Recent studies show that near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has the potential to improve the performance of sentinel lymph node (SLN) mapping. The current cohort study was designed to assess the value of the combination of ICG and methylene blue (MB) dye in patients undergoing SLN biopsy.

Methods

A prospective self-controlled trial was designed to detect the difference in the detection efficacies of ICG, MB, and combined ICG and MB (ICG + MB) navigation methods. Between 2010 and 2013, 198 consecutive early breast cancer patients eligible for sentinel lymph node biopsy were enrolled and 200 biopsy procedures were performed by injection of both ICG and MB. SLNs were searched and removed under the guidance of fluorescence and/or blue dye. The mapping characteristics, the detection rate of SLNs and positive SLNs, and the number of SLNs of ICG, MB, and ICG + MB were compared. Injection safety of ICG and MB was evaluated.

Results

Fluorescence imaging of lymphatic flow, which is helpful to locate the incision site, could be seen in 184 of 200 procedures. The nodal detection rate of ICG, MB, and ICG + MB samples was 97, 89, and 99.5% (χ 2 = 26.2, p < 0.001), respectively, with the combination method yielding a superior identification result. The addition of ICG to the MB method resulted in the identification of more lymph nodes (median 3 versus 2) and more positive axillas (22.7% involved axillas were discovered by fluorescence only) than either method alone. No acute or chronic allergic reaction was observed in this study. However, 23 patients (23/82) who received breast-conserving therapy reported temporary skin staining, and 5 patients had permanent tattooing. Palpable subcutaneous nodules at the injection sites were reported in nine patients. There were no reports of skin necrosis.

Conclusions

The lymphatic navigation by ICG fluorescence detects SLNs at a high detection rate and improves the mapping performance when added to the MB method. The novel ICG + MB dual tracing modality, without involvement of radioactive isotopes, exhibits great potential as an alternative to traditional standard mapping methods.

Trial registration

ACTRN12612000109808. Retrospectively registered on 23 January 2012.

Keywords

  • Breast neoplasm
  • Indocyanine green
  • Sentinel lymph node biopsy
  • Lymphography

Background

Knowledge of the regional lymph node status is essential to establishing staging and prognostic outcomes of breast cancer. Axillary lymph node staging by sentinel lymph node biopsy (SLNB) is a widely used method and is now regarded as a standard of care in patients without clinical evidence of axillary lymph node metastasis in early breast cancer [1].

The existing standard SLNB method is a dual technique involving the injection of a technetium-99m (99mTc)-labeled nanocolloid and blue dye [2]. Despite the reports of effectiveness and good safety data, the involvement of radioisotopes creates logistical challenges, including isotope handling and disposal, staff training, and legislative requirements, as well as the reluctance of patients and personnel to be exposed to radiation. Constraints of radioisotopes have led to the development of non-radioactive alternative methods. Quite a few institutions have attempted to perform SLNB using blue dye alone [36]. As an alternative dye tracer, methylene blue (MB) does not have the restrictions of isosulfan blue and patent blue, such as life-threatening anaphylaxis and international shortage. The MB alone method has gained widespread popularity worldwide, especially in developing countries like China [711]. However, some investigators maintained that the use of blue dye alone leads to a lower SLN identification rate [12], which might draw concerns about the potential adverse impact on long-term prognosis [13].

SLNB with near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) was recently introduced and was reported to be a highly sensitive method for SLN detection [1416]. In this method, ICG is injected, and its progress through the lymphatic ducts to SLNs is tracked using an excitation illumination system combined with a high-sensitivity camera that detects the emitted fluorescence. As NIR could be transcutaneously detected similar to radioactive agents, the combination of ICG and MB shows great potential as an alternative to standard dual mapping methods [14, 1719]. Hence, we designed the present prospective study to evaluate whether combining ICG and MB could improve the SLN tracing performance in early breast cancer patients.

Methods

Patients

Between January 2010 and March 2013, a total of 198 consecutive patients (196 with unilateral cancers and 2 with bilateral disease) with early breast cancer, as confirmed by core needle biopsy or open biopsy, and clinically negative axillas were enrolled in the present study. The present study was approved by the Ethical Committee of Peking University People’s Hospital, Beijing and was registered as the Australian and New Zealand Clinical Trials Registry No 12612000109808. Patients with tumors > 5 cm, clinically or radiologically suspicious lymph nodes, inflammatory breast cancer, distant metastatic tumor, previous axillary surgery, or hypersensitivity to iodine or indocyanine green were excluded from the study. Written informed consent was obtained from all patients.

Procedure

MB (Jizhou Pharmaceutical, Suzhou, China) was diluted to a final concentration of 1% with saline from an original concentration of 2%. The ICG (Dandong Pharmaceutical, Jilin, China) agent used in this study included iodine. Twenty-five milligrams of stock ICG powder was dissolved in 10 ml of distilled water and was then diluted to a final concentration of 0.05%. Immediately before surgery, 1 ml of 1% MB was subdermally injected into the periareolar region. Five minutes later, 1 ml of ICG solution (1.25 mg) was intradermally injected into two to four sites in the same periareolar area region. The movement of the tracer in the periareolar region was facilitated by massage. ICG fluorescence was stimulated and detected by a hand-held fluorescence detector (MingDe Medicine, China, elicitation wavelength of 780 nM and acquisition wavelength of 735 nM). The lymphatic drainage was traced by fluorescence navigation and visualized on a monitor in real time. The fluorescent signal was followed from the injection sites to the axilla (occasionally to the intramammary region), and an incision was made to start the SLNB where the fluorescence disappeared. Fluorescent lymph nodes (ICG-positive) and/or blue nodes (MB-positive) were localized and excised. Then, the axilla was inspected for residual fluorescent or blue nodes. The excised nodes were categorized as fluorescent+/blue+, fluorescent+/blue-, or fluorescent−/blue+. All removed nodes were sent for histological examination following an institutional standard protocol. Patients with positive SLNs underwent axillary clearance, and benign axillas were spared.

Adverse events, including skin lesions, allergic reactions and any other complication considered to be caused by the tracers, were recorded in indicated cases according to patients’ complaint, physical examination, and imaging tests.

Study design and statistical analysis

The trial was composed to evaluate whether the ICG + MB modality was superior to MB alone in terms of its ability to detect SLNs.

The detection rate was calculated by the number of successful mappings divided by the total number of mapping cases performed for each modality. To estimate the number of samples, we assumed a detection rate of 85% for the control method (dye alone) [20] and set δ at 5%. We found that 200 procedures were needed to demonstrate superiority between the two methods with a power of 80% and a significance (α) of 5%. The calculation was performed by using PASS 11 software (NCSS, LLC. Kaysville, Utah, USA).

For statistical analysis, SAS software (version 9.2) was used. A chi-square test was used to compare the detection rates. To compare the median number of SLNs between groups, a non-parametric Mann-Whitney U test was used.

Results

ICG mapping

Patient and tumor characteristics are shown in Table 1. Transcutaneous fluorescent lymphography was visible in 184 breasts. A routine incision used in dye-guided SLNB in the armpit was made in the other 16 procedures. When the skin and subdermal fat were incised, fluorescent lymph nodes could be successfully detected in 194 axillas, including 15 cases with no visible fluorescent flow in the skin (Fig. 1).
Table 1

Patient and tumor characteristics

Characteristics

N

%

Age

 52 (33–74)

  

 ≥ 50

112

56.5

 < 50

86

43.4

T

 T1

138

69

 T2

61

30.5

 T3

1

0.5

Histological type

 In situ

23

11.5

 Microinvasive

12

6

 Invasive ductal

134

77

 Invasive lobular

15

7.5

 Other

16

8

Tumor grade

 I

22

11

 II

112

56

 III

28

14

 NA

38

19

Molecular subtype (immunohistochemical)

 Luminal A

65

32.5

 Luminal B

78

39

 Her-2 positive

9

4.5

 Triple negative

44

22

 NA

4

2

Laterality

 Left

105

52.5

 Right

95

47.5

Quadrant

 Upper outer

94

47

 Lower outer

26

13

 Upper inner

55

27.5

 Lower inner

17

8.5

 Central

8

4

Body mass index (BMI)

 < 19

10

5

 19–25

120

60.6

 ≥ 25

68

34.3

 ≥ 30

0

0

Fig. 1
Fig. 1

SLN resection mapping by ICG fluorescence. a Two streams of dermal lymphatic vessels. b One stream of dermal lymphatic vessels (IS—injection site; white arrow—fluorescent lymph vessels). c SLN highlighted by ICG fluorescence (white arrow). d Fluorescence disappeared after all the SLNs were removed

Nodal identification performance

The detection rates of the tracer agents are shown in Table 2. The overall SLN detection rates for the ICG and dual methods were 97 and 99.5%, respectively, while the detection rate for dye alone was 89% (χ 2 = 26.2, p < 0.001). The difference between the ICG + MB tracing modality and MB alone was therefore 10.5%. The 95% confidence interval (CI) for this difference was 6.1 to 14.9%. Since this CI does not include the superiority margin of 5%, we are powered to reject the null hypothesis and conclude that the combination of ICG and MB is superior to MB alone.
Table 2

Detection rates of various tracers

 

N

Detection rate (%)

Fluorescent+/blue+

199

99.5

Blue+

178

89.0

Fluorescent+

194

97.0

An age ≥ 50, a BMI ≥ 25, an outer upper quadrant tumor and a larger tumor size were associated with a reduced detection rate for the MB alone method but not for the ICG or combination method.

A total of 616 SLNs were detected by one or both methods. The median numbers of SLNs detected by the ICG (fluorescent−/blue−), MB alone (fluorescent−/blue+), and the combination methods (fluorescent+/blue+) were 3 (range 1–8), 2 (range 1–6), and 3 (range 1–8), respectively. The median numbers of SLNs identified by the ICG and combination methods were significantly higher than those identified by MB alone (p < 0.001).

Fifty-eight nodes out of 616 SLNs contained metastases. Twenty nodes were fluorescent, 4 were blue, and 34 were double-positive (Table 3), and the numbers of axillary nodes diagnosed by each modality were 10, 2, and 32, respectively. Hence, 22.7% positive axillas would have been missed if the dye only method had been the sole method used in this cohort.
Table 3

Positive SLNs and patients detected by different methods

  

Detected positive nodes

Detected positive axillas(patients)

Number (%)

Number (%)

Fluorescent+

Blue+

34 (58.6)

32 (72.7)

Fluorescent+

Blue−

20 (34.5)

10 (22.7)

Fluorescent−

Blue+

4 (6.9)

2 (4.6)

Total

58 (100)

44 (100)

Adverse effects

No acute or chronic allergic reactions were observed in this study. A total of 148 patients reported colored urine, most of which disappeared in 24 h. Twenty-three patients (23/82) who received breast-conserving therapy reported temporary skin staining, which was a complication of both ICG and MB, and only five patients had permanent tattooing (we defined “permanent” as skin pigmentation ≥ 6 months), which was due to the injection of MB. Although palpable subcutaneous nodules, probably due to fat necrosis at the injection sites, were reported in nine patients, no patient needed a diagnostic biopsy, and there were no reports of skin necrosis.

Discussion

This was a prospective study to assess whether the addition of the promising ICG method to the widely used MB dye method improved the SLN identification performance in patients with early breast cancer. We conclude that the detection rate of the fluorescence and dye combination was significantly higher than that of the MB dye alone (99.5 vs. 89%). This result is consistent with previous studies [21, 22].

The high identification rate and accurate diagnosis performance of the ICG + MB modality provide the possibility of a non-radioactive alternative method for dual tracing of SLNs. It would be fairly attractive to abandon the use of radioactive agents, especially in institutes where radioisotopes are not readily available. Ballardini B. from the European Institute of Oncology reported a trial comparing ICG with a 99mTc-labeled radiotracer in 134 patients. This equivalently designed study was powered to demonstrate that the ICG method yielded a high detection rate of SLNs that was not inferior to that of radiotracers [23]. Although Ahemd M. subsequently criticized the absence of a standard dual mapping technique in Ballardini B’s study [24], replacing the radiotracer with ICG showed promise. A recent meta-analysis performed by Sugie T. [25] confirmed this assumption. Since the current study was designed as a superiority trial with δ set at 5%, we can draw the conclusion from the positive results that the combined use of ICG and MB is more effective than dye alone, as we observed an increase in the detection rate by 10.5%, or in other words, a 5% improvement, which is comparable to the difference between standard radioisotope included method and dye alone [26]. Although there were few studies that compared the identification performance of ICG with standard radiotracer and dye combination method directly, the combined use of ICG and dye is deemed to be the most likely alternative to the current standard.

In addition to the detection performance improvement, ICG may bring accuracy benefits. First and foremost, the extreme sensitivity of ICG contributed to the harvest of extra SLNs that were undetected by the dye. In the current study, the median number of the SLNs detected by ICG + MB was 3, which was greater than that of SLNs detected by MB alone. Similar results were also found in previous studies [18, 21, 27, 28]. Results of two meta-analyses revealed that acceptably more SLNs (three to four nodes) were related to a higher detection rate and a more accurate prognosis, whereas only one SLN was found to not adequately represent the axillary status [29, 30]. Since ICG detected more SLNs, we speculated that the higher sensitivity of ICG was due to its higher visibility via the high-resolution near-infrared equipment in contrast with the perception of dye uptake via the naked eye and that this higher visibility might improve the detection rate of positive nodes. As a consequence, identification of additional positive SLNs missed by the dye method may elevate the accuracy of the biopsy procedure. The present trial demonstrated that adding ICG to MB tracing might contribute to avoiding a false-negative assessment of the axillary status in 22.7% of patients. However, the potential benefits should be confirmed by randomized trials.

As reported before, ICG-guided SLNB had several limitations. For example, the tissue penetration capacity of NIR fluorescence is lower than that of gamma rays. One concern is that the limitation of penetration distance of ICG based tracing would result in worse performance in obese patients. Though no axillary skin compression technique used in the current study which was reported by Kitai [31], we found no significant difference between obese patients (BMI ≥ 25) and non-obese patients. According to Grischke’s research, there was no difference in the detection rate when a cut-off of BMI ≥ 30, or ≥ 35 were used, whereas detection with ICG was only difficult in patients when BMI > 40 [32]. As shown by our study, patients with very high BMI were rare in China. Hence, this limitation would not be an obstacle to the clinical use of ICG. Fluorescence quenching effect was another point regarding the efficacy of ICG navigation. It was reported that the ICG exhibited intense quenching (i.e., reduction of fluorescence emission) as its concentration was increased. Based on their results of a small cohort, Mieog recommended an injection dose of 0.62 mg as an optimal dose for ICG [33]. However, several studies that reported varied doses (between 0·625 and 15 mg in a volume of between 1 and 5 ml) yielded similarly high detection rates [14]. There was no consensus on the optimal dose of ICG. Based on the lymphatic visibility, we chose 1.25 mg in 1 ml as our injection dose. The excellent navigation performance indicated that this dose was clinically acceptable. Adverse effects such as sensitive reaction and skin lesion are the primary concerns regarding the safety of dye-based mapping [34, 35]. In this cohort, we found no allergic cases. Interstitial use in lymph mapping rather than intravenous injection may be the main cause of the fewer instances of allergic reaction. Moreover, absence of an allergic reaction may be due to the exclusion of iodine hypersensitive patients. The main dermal complications included temporary skin staining, permanent tattooing, and subcutaneous nodules at the injection sites. Although these skin complications may lead to certain degrees of anxiety in stressed patients, these complications would be acceptable to most patients. The relatively good safety results were similar to results from previous meta-analyses [14, 19].

The current study had two shortcomings. First, we did not compare the ICG + MB method to the 99mTc + MB method. However, the excellent performance of this dual mapping method might be indirectly confirmed by a superiority test at 5%. Furthermore, regardless of the benefits of self-controlled design, including elimination of individual variation, decreased sample size, and good statistical efficiency, confounding bias may occur. In this setting, after all fluorescent nodes have been detected, surgeons might tend to end the procedure rather than work so hard to search for more blue nodes. This might result in an underestimation of the efficacy of MB and an overestimation of the performance difference.

In summary, this study reveals a high detection rate of ICG and the superiority of combining ICG fluorescence with blue dye in early breast cancer detection strategies. It is proposed that a combination of ICG fluorescence and blue dye (MB) method can be used in centers where radioactive agents are unavailable. Furthermore, for the excellent performance of this novel dual tracing modality, a better non-radioactive substitute for the combination of radioisotope and blue dye beckons.

Conclusion

The lymphatic navigation by ICG fluorescence detects SLNs at a high detection rate and improves the mapping performance when added to the dye method. The novel ICG + MB dual tracing modality, without involvement of radioactive isotopes, exhibits great potential as an alternative to traditional standard mapping methods.

Abbreviations

99mTc: 

Technetium-99m

BMI: 

Body mass index

CI: 

Confidence interval

ICG: 

Indocyanine green

MB: 

Methylene blue

NIR: 

Near-infrared

SLN: 

Sentinel lymph node

SLNB: 

Sentinel lymph node biopsy

Declarations

Acknowledgements

Not applicable.

Funding

This study was sponsored by the Capital Medical Development Scientific Research Fund (2014-2-4083). The funding body did not participate in the design of the study; the collection, analysis, and interpretation of data; or the writing of the manuscript.

Availability of data and materials

Please contact the corresponding author for data requests.

Authors’ contributions

JG participated in the study design and coordination and participated in the data analysis. HY participated in the study design, data collection, and data analysis and participated in drafting the manuscript. Shu Wang conceived the study and participated in its design and coordination. YC, ML, FX, PL, BZ, FT, LC, HL, and SW participated in the clinical study implementation and data collection. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Peking University People’s Hospital, Beijing. Written informed consent from all patients was obtained before the operation. No individual data were contained in this work.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Peking University People’s Hospital Breast Center, NO 11, Xizhimen South Street, Xicheng District, Beijing, 10044, People’s Republic of China

References

  1. Lyman GH, Somerfield MR, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract. 2017;13:196–8.View ArticlePubMedGoogle Scholar
  2. Giammarile F, Alazraki N, Aarsvold JN, Audisio RA, Glass E, Grant SF, Kunikowska J, Leidenius M, Moncayo VM, Uren RF, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol I. 2013;40:1932–47.View ArticleGoogle Scholar
  3. Eser M, Kement M, Kaptanoglu L, Gecer M, Abamor E, Tutal F, Balin S, Kurt N, Uzun H. A prospective comparative study to assess the contribution of radioisotope tracer method to dye-only method in the detection of sentinel lymph node in breast cancer. BMC Surg. 2013;13:13.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Radovanovic Z, Golubovic A, Plzak A, Stojiljkovic B, Radovanovic D. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. Eur J Surg Oncol. 2004;30:913–7.View ArticlePubMedGoogle Scholar
  5. Meyer-Rochow GY, Martin RC, Harman CR. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. ANZ J Surg. 2003;73:815–8.View ArticlePubMedGoogle Scholar
  6. Ang CH, Tan MY, Teo C, Seah DW, Chen JC, Chan MY, Tan EY. Blue dye is sufficient for sentinel lymph node biopsy in breast cancer. Br J Surg. 2014;101:383–9.View ArticlePubMedGoogle Scholar
  7. Zaazou M, Mahran K, Merhem I. Sentinel lymph node biopsy using methylene blue dye in early breast cancer. Is it truly reliable? Egypt J Surg. 2010;29:132–6.Google Scholar
  8. Mathelin C, Croce S, Brasse D, Gairard B, Gharbi M, Andriamisandratsoa N, Bekaert V, Francis Z, Guyonnet JL, Huss D, et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res. 2009;29:4119–25.PubMedGoogle Scholar
  9. Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg. 2008;196:228–33.View ArticlePubMedGoogle Scholar
  10. Varghese P, Abdelrahman A, Akberali S, Mostafa A, Gattuso J, Carpenter R. Methylene blue dye: a safe and effective alternative for sentinel lymph node localisation. Eur J Surg Oncol. 2007;33:1134.View ArticleGoogle Scholar
  11. Blessing WD, Stolier AJ, Teng SC, Bolton JS, Fuhrman GM. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg. 2002;184:341–5.View ArticlePubMedGoogle Scholar
  12. Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92:1494–7.View ArticlePubMedGoogle Scholar
  13. Niebling MG, Pleijhuis RG, Bastiaannet E, Brouwers AH, van Dam GM, Hoekstra HJ. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol. 2016;42:466–73.View ArticlePubMedGoogle Scholar
  14. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15:e351–62.View ArticlePubMedGoogle Scholar
  15. Tagaya N, Yamazaki R, Nakagawa A, Abe A, Hamada K, Kubota K, Oyama T. Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. Am J Surg. 2008;195:850–3.View ArticlePubMedGoogle Scholar
  16. Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211–5.View ArticlePubMedGoogle Scholar
  17. Chiu CC. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence (Br J Surg 2009;96:1289–1294). Br J Surg. 2010;97:455–6.View ArticlePubMedGoogle Scholar
  18. Murawa D, Hirche C, Dresel S, Hunerbein M. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg. 2009;96:1289–94.View ArticlePubMedGoogle Scholar
  19. Xiong L, Gazyakan E, Yang W, Engel H, Hunerbein M, Kneser U, Hirche C. Indocyanine green fluorescence-guided sentinel node biopsy: a meta-analysis on detection rate and diagnostic performance. Eur J Surg Oncol. 2014;40:843–9.View ArticlePubMedGoogle Scholar
  20. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, Vennekotter DJ, Turk PS, Tate PS, Sardi A. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.View ArticlePubMedGoogle Scholar
  21. Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, Ikeda T, Yoshimura K, Niimi M, Shimizu A, Toi M. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013;20:2213–8.View ArticlePubMedGoogle Scholar
  22. Hirano A, Kamimura M, Ogura K, Kim N, Hattori A, Setoguchi Y, Okubo F, Inoue H, Miyamoto R, Kinoshita J, et al. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients. Ann Surg Oncol. 2012;19:4112–6.View ArticlePubMedGoogle Scholar
  23. Ballardini B, Santoro L, Sangalli C, Gentilini O, Renne G, Lissidini G, Pagani GM, Toesca A, Blundo C, Del Castillo A, et al. The indocyanine green method is equivalent to the 99mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol. 2013;39:1332–6.View ArticlePubMedGoogle Scholar
  24. Ahmed M, Douek M. What is the clinical relevance of discordance between radioisotope alone and indocynanine green in sentinel lymph node biopsy for breast cancer? Eur J Surg Oncol. 2014;40:786.View ArticlePubMedGoogle Scholar
  25. Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017;22:11–7.View ArticlePubMedGoogle Scholar
  26. O Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, Borgen PI, Cody HS 3rd. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186:423–7.View ArticleGoogle Scholar
  27. Hojo T, Nagao T, Kikuyama M, Akashi S, Kinoshita T. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast. 2010;19:210–3.View ArticlePubMedGoogle Scholar
  28. Hirche C, Murawa D, Mohr Z, Kneif S, Hunerbein M. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat. 2010;121:373–8.View ArticlePubMedGoogle Scholar
  29. Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer-Am Cancer Soc. 2008;113:30–7.Google Scholar
  30. Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park BW. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer. 2011;14:296–300.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kitai T, Kawashima M. Transcutaneous detection and direct approach to the sentinel node using axillary compression technique in ICG fluorescence-navigated sentinel node biopsy for breast cancer. Breast Cancer. 2012;19:343–8.View ArticlePubMedGoogle Scholar
  32. Grischke EM, Röhm C, Hahn M, Helms G, Brucker S, Wallwiener D. ICG fluorescence technique for the detection of sentinel lymph nodes in breast cancer: results of a prospective open-label clinical trial. Geburtsh Frauenheilk. 2015;75:935–40.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Mieog JSD, Troyan SL, Hutteman M, Donohoe KJ, van der Vorst JR, Stockdale A, Liefers G, Choi HS, Gibbs-Strauss SL, Putter H, et al. Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol. 2011;18:2483–91.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Wolf S, Arend O, Schulte K, Reim M. Severe anaphylactic reaction after indocyanine green fluorescence angiography. Am J Ophthalmol. 1992;114:638–9.View ArticlePubMedGoogle Scholar
  35. Stradling B, Aranha G, Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg. 2002;184:350–2.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement